Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achilles Therapeutics Plc (NQ: ACHL )

1.240 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,480
Open 1.240
Bid (Size) 1.230 (16)
Ask (Size) 1.270 (19)
Prev. Close 1.240
Today's Range 1.200 - 1.280
52wk Range 0.7500 - 4.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga

Performance

YTD
+18.10%
+18.10%
1 Month
+18.10%
+18.10%
3 Month
-32.61%
-32.61%
6 Month
-52.12%
-52.12%
1 Year
-67.37%
-67.37%

More News

Read More
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Achilles Therapeutics PLC
Via Globe NewsWire
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
From Achilles Therapeutics PLC
Via Globe NewsWire
Recap: Achilles Therapeutics Q2 Earnings
Via Benzinga
Achilles Therapeutics: Q1 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Why UiPath Shares Are Trading Higher By Around 8%; Here Are 24 Stocks Moving Premarket
Via Benzinga
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
From Achilles Therapeutics PLC
Via Globe NewsWire
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
From Achilles Therapeutics PLC
Via Globe NewsWire
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via Globe NewsWire
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
From Achilles Therapeutics PLC
Via Globe NewsWire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Tesla, Coinbase Global And 41 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why U.S. Stocks Are Trading Higher; Goldman Sachs Tops Q2 Views
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in CHIRON Phase 1/2a Trial for Advanced NSCLC
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies
From Secarna Pharmaceuticals GmbH & Co. KG
Via AccessWire
51 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
48 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.